Early intervention is important in many illnesses, including psychosis, so treatment can begin as early as possible for best outcomes, explained Jacob Ballon, MD, MPH, clinical associate professor, psychiatry and behavioral sciences, Stanford University. He also discussed a resource for learning more about early intervention.
Early intervention is important in many illnesses, including psychosis, so treatment can begin as early as possible for best outcomes, explained Jacob Ballon, MD, MPH, clinical associate professor, psychiatry and behavioral sciences, Stanford University. He also discussed a resource for learning more about early intervention.
Transcript
Why is early recognition and intervention for young people with psychosis so important?
Well, early intervention for psychosis is important because we want to begin treatment at the earliest stage of illness. Just like we would want to begin treatment for cancer at the earliest stage of illness, there’s no reason to want to wait until far longer before somebody begins treatment. We know that the duration of untreated psychosis correlates with treatment outcome, and in the United States in the RAISE-ETP study we saw that the median duration of untreated psychosis was 74 weeks. We need to make that sooner so that people get into treatment earlier and achieve better outcomes.
What are some resources for clinicians seeking to learn more about early intervention in psychosis?
I’m excited to present a new book on intervening early in psychosis that I wrote with my coauthors Dr Hardy, Dr Noordsy, and Dr Adelsheim. The book is available through the APA Press and through Amazon, and it provides a comprehensive look for all members of the treatment team in treating early psychosis. It’s written through using case vignettes and other ways to help people to appreciate all of the different aspects in intervening early in psychosis. There’s been a tremendous increase in early intervention clinics, but many people are wondering exactly what that should look like. This book will help provide a comprehensive look on all of the different factors that one should consider when developing a comprehensive treatment for early psychosis.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More